This is the authors' abstract. We don't add key points for this paper.
SDMT is simpler to administer than PASAT3 and may be slightly more sensitive to MS cognitive impairment. It could thus be a suitable test to assess cognitive impairment routinely in people with relapsing-remitting multiple sclerosis.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
López‐Góngora et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: